Nyxoah Secures $110M in Aggregate Financing, Bolstering Genio U.S. Launch
NYXH is trading near its 52-week low of $1.26 (3.2% above the low) on elevated volume (8.3× avg).
Summary
Nyxoah has secured $110 million in aggregate financing. This includes the recently completed $95 million equity financing and an anticipated $15 million second tranche from its European Investment Bank loan. This critical capital infusion directly addresses the company's previously disclosed "going concern" doubts and very short cash runway. The funds are earmarked to accelerate the U.S. commercial launch of its Genio system, a key product for the medical technology company. The $15 million EIB loan tranche is expected by the end of June 2026.
At the time of this announcement, NYXH was trading at $1.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $130.9M. The 52-week trading range was $1.26 to $8.59. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.